Journal of Pharmacology & Pharmacotherapeutics最新文献_第8页

Mucormycosis - The black menace in COVID-19 毛霉菌病-新冠肺炎的黑色威胁

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-10-01 DOI: 10.4103/jpp.jpp_93_21

C. Pattanayak, Sougata Sarkar, V. Srivastava

{"title":"Mucormycosis - The black menace in COVID-19","authors":"C. Pattanayak, Sougata Sarkar, V. Srivastava","doi":"10.4103/jpp.jpp_93_21","DOIUrl":"https://doi.org/10.4103/jpp.jpp_93_21","url":null,"abstract":"The current outbreak of second wave of COVID-19 in India has seen the rise of opportunistic infections, a deadly one being mucormycosis or “black fungus.” As of now, there are over 9000 cases of this deadly disease which have been reported from several states in India. Nine states in India including Punjab, Uttar Pradesh, Rajasthan, and Bihar have declared mucormycosis as an epidemic. There are five types of mucormycosis – rhino-orbital-cerebral, pulmonary, gastrointestinal, cutaneous, and disseminated. Out of these, rhino-orbital-cerebral and pulmonary mucormycoses are most common in post-COVID patients. The clinical presentation of such patients include cough, fever, breathlessness, chest pain, sinusitis, pain on one side of the face with lack of sensation and proptosis of eye. Diagnosis could be done through analysis of clinical findings, direct microscopy, serum antigen tests, culture, histopathology, radio imaging, and polymerase chain reaction/matrix-assisted laser desorption ionization time-of-flight. Treatment will include preventive measures taken at home or at hospital for post-COVID patients. Medical treatment of mucormycosis mainly includes installing a central catheter (line), maintaining adequate systemic hydration, and infusion of normal intravenous saline before antifungal amphotericin B infusion. Since amphotericin is nephrotoxic, alternative drugs, such as posaconazole or isavuconazole, can be suggested. Adjuvant therapy with caspofungin, deferasirox, statins, aspirin, and hyperbaric oxygen may have to be considered as well. Extensive surgical debridement can also be suggested to remove all necrotic tissues. This review emphasizes the different aspects of mucormycosis such as epidemiology, etiopathogenesis, risk factors, diagnosis, preventive measures, and treatment strategies that can be adopted to tackle this fungal menace in COVID-19.","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"12 1","pages":"151 - 156"},"PeriodicalIF":0.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46075299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Clinical Pharmacist Interventions in Resolving Drug-Related Problems in Patients with Systemic Autoimmune Disorders 临床药师干预对解决全身性自身免疫性疾病患者药物相关问题的影响

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-10-01 DOI: 10.4103/jpp.jpp_149_21

S. Sah, Subramanian Ramaswamy, M. Ramesh

引用次数: 1

Oliceridine - Breakthrough in the Management of Pain Oliceridine-疼痛管理的突破

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-10-01 DOI: 10.4103/jpp.jpp_116_21

D. Elango, D. Malathi, PriyadharsiniRaman Palanisamy

{"title":"Oliceridine - Breakthrough in the Management of Pain","authors":"D. Elango, D. Malathi, PriyadharsiniRaman Palanisamy","doi":"10.4103/jpp.jpp_116_21","DOIUrl":"https://doi.org/10.4103/jpp.jpp_116_21","url":null,"abstract":"Oliceridine an intravenous opioid approved in 2020 by the Food and Drug Administration (FDA) to treat moderate-to-severe pain. Oliceridine developed with a novel mechanism that is biased agonism toward G-protein-coupled receptors pathway. Being biased agonist, it does not activate beta arrestin pathway responsible for opioid-related adverse events (ORAE), especially respiratory depression. Because of the novel mechanism, oliceridine has paved a pathway to decrease ORAE. Oliceridine has received breakthrough status by FDA. However, FDA denied oliceridine approval and withdrew breakthrough status by 2019. FDA made this decision because of the inadequacy of the safety data. Abuse potential and QT prolongation studies are conducted as per FDA recommendation in the year 2019; oliceridine was approved for moderate to severe pain in adults. This review will briefly summarize the pharmacological properties and study results of oliceridine in the management of pain. Thorough literature search was done for the efficacy and safety of oliceridine, search was done in electronic database of PubMed and Cochrane from inception till June 2021. Oliceridine was found to be effective in acute severe pain with less OREA when compared to morphine. Oliceridine has many drawbacks than what is hypothesized earlier, but this approach has opened new options for patients suffering from severe pain. Long-term effect of oliceridine has to be monitored to assess the effects of biased agonism.","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"12 1","pages":"157 - 162"},"PeriodicalIF":0.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44852363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prof. M. N. Ghosh: A Pharmacologist Beyond Compare M. N. Ghosh教授:一位无与伦比的药理学家

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-10-01 DOI: 10.4103/jpp.jpp_179_21

Syed Ziaur Rahman

引用次数: 0

Monitoring Adverse Drug Reactions and Incidence of Potential Statin-Drug Interactions 监测药物不良反应和潜在他汀类药物相互作用的发生率

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-10-01 DOI: 10.4103/jpp.jpp_79_21

Kleva Shpati, G. Stroni, Erina Hilaj, Aurora Napuçe, G. Rexha

{"title":"Monitoring Adverse Drug Reactions and Incidence of Potential Statin-Drug Interactions","authors":"Kleva Shpati, G. Stroni, Erina Hilaj, Aurora Napuçe, G. Rexha","doi":"10.4103/jpp.jpp_79_21","DOIUrl":"https://doi.org/10.4103/jpp.jpp_79_21","url":null,"abstract":"Cardiovascular diseases are the first disease in Albania that caused mortality and morbidity according to the Public Health Institute the Statistical Institute of Albania.[1,2] Hydroxymethylglutaryl-CoA reductase inhibitors (known as statins) are widely used as lipid-lowering drugs. They caused adverse events such as myotoxicity, renal, and hepatic problems which are considerably elevated in combination with other drugs. Drug–drug interactions (DDIs) can result in a change in either drug efficacy or toxicity. The value of therapy is defined by ineffectiveness or increased toxicity. Statins are the therapeutic class of medicines that reduce morbidity and mortality in patients with atherosclerotic cardiovascular disease.[3,4] Adverse events caused by DDI with clinical significance are preventable. DDIs involving statins include individual pharmacokinetics characteristics (e.g., binding affinity, half-life, dose of medications, and timing and sequence of administration duration of therapy) patients’ factors (e.g., age, sex, lifestyle, disease implicating metabolism hepatic, renal impairments and cardiac failure), genetic polymorphism, hypersensitivity, etc. Physicians choose a noninteracting alternative, but if none is available, they prescribe in combination by evaluating the benefits and risks of the co‐commitment of medications.[5,6]","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"12 1","pages":"172 - 174"},"PeriodicalIF":0.2,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48999843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-Induced Erectile Dysfunction: Two Interesting Cases 药物性勃起功能障碍:两个有趣的案例

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-10-01 DOI: 10.4103/jpp.jpp_129_21

S. Samajdar, Shatavisa Mukherjee, Dipan Saha, D. Jumani, S. Tripathi

引用次数: 2

Eosinophilic Gastroenteritis: An Unclear Etiology of Ascites and Dramatic Response to Steroids Can be a Diagnostic Key 嗜酸性粒细胞性胃肠炎：腹水病因不明，对类固醇反应强烈可能是诊断关键

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-10-01 DOI: 10.4103/jpp.jpp_104_21

A. Bhardwaj, Shoma Mukherjee

引用次数: 0

Hurdles in Mandatory Generic Medicine Prescription 强制仿制药处方的障碍

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-07-01 DOI: 10.4103/jpp.jpp_74_21

V. Virdi, Money Gupta, Rohit Gupta

引用次数: 0

A Mini Review: Mucormycosis in Coronavirus Disease-19, Host-Iron Assimilation, and Probiotics as Novel Therapy 综述：毛霉菌病与冠状病毒病-19、宿主铁同化和益生菌作为新疗法

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-07-01 DOI: 10.4103/jpp.jpp_58_21

A. Bhardwaj, V. Roy, Indu Priyadarshini

引用次数: 1

Effect of Homoharringtonine as a Combined Regimen for Acute Myeloid Leukemia 高三尖杉酯碱联合方案治疗急性髓细胞白血病疗效观察

IF 0.2

Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-07-01 DOI: 10.4103/jpp.jpp_52_21

Abinaya Muralidharan, J. Scott, L. Joseph, S. Jeyabalan

{"title":"Effect of Homoharringtonine as a Combined Regimen for Acute Myeloid Leukemia","authors":"Abinaya Muralidharan, J. Scott, L. Joseph, S. Jeyabalan","doi":"10.4103/jpp.jpp_52_21","DOIUrl":"https://doi.org/10.4103/jpp.jpp_52_21","url":null,"abstract":"Homoharringtonine (HHT), a cephalotaxus alkaloid has shown promising results in the treatment of several hematological disorders such as chronic myeloid leukemia, acute myeloid leukemia (AML), and myelodysplastic syndrome. It is known for its unique mechanism of action by which it prevents the initial elongation step of protein biosynthesis. Hence, it is used in hematological malignancies where it synergistically potentiates the action of other drugs and induces apoptosis. The relevant studies published were searched using an electronic database from 2002 to 2019. The articles published in English were only considered. Search engines such as PubMed, MEDLINE, Google Scholar, and Semantic scholar were used. In this review, we have discussed the effect of HHT in combination with other chemotherapeutic agents for AML with or without genetic mutation specification and the future perspective of these regimens. Although standard treatment options exist for most of these diseases, still cure rates are low with reported morbidity and the drug resistance emergence is pervasive. Thus, novel treatment approaches are crucial for better outcome. Alternative regimens together with HHT have not been a standard practice, although they have shown a very good potential in AML patients. Many of the combinations were also proved to be safe and effective with very low toxic potential. All these data outcomes of various combinations under different scenarios exhibit that HHT has promising results in the treatment of AML which may lead to its approval in the upcoming years.","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":"12 1","pages":"110 - 114"},"PeriodicalIF":0.2,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46890772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0